Patients with HDO, N = 26 | Patients with continuous follow-up, N = 52 | p-value | |
---|---|---|---|
Cumulativea disease activity and function | |||
DAS28 | 2.8 (1.5–3.2) | 1.7 (1.2–2.2) | 0.004 |
N° of flares/patient | 1 (1–2) | 0 (0–1) | 0.000 |
N° (%) of patients with sustained remission at outcome | 17 (65.4) | 48 (92.3) | 0.007 |
SF36 score | 86 (70.6–91.8) | 89.3 (81.1–92) | 0.12 |
N° of schedule visits | 4 (3–4) | 3 (3–4) | 0.02 |
Cumulativea treatment | |||
N° (%) of patients on corticosteroids | 9 (34.6) | 23 (44.2) | 0.47 |
N° of DMARD/patient | 1 (1–2) | 1 (1–1) | 0.10 |
Cumulativea patient’s treatment behavior | |||
% of follow-up on persistence | 82.9 (45–100) | 84.5 (65–100) | 0.38 |
N° (%) of patients with persistence <50% | 7 (26.9) | 6 (11.5) | 0.11 |
N° (%) of patients recurrent non-persistent | 8 (30.8) | 19 (36.5) | 0.8 |